Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transient receptor potential cation channel subfamily C member 7 (TRPC7)
- Target
- TRPC7
- Molecular classification
- Ion channel, Transient receptor potential channel, Non-selective cation channel
01
Overview
Transient receptor potential cation channel subfamily C member 7 (TRPC7) is a non-selective cation channel found in humans and other mammals. It is part of the transient receptor potential (TRP) superfamily—specifically, the canonical (TRPC) subfamily. TRPC7 is structurally characterized by six transmembrane segments and forms a channel permeable to mono- and divalent cations, with a particular preference for Ca²⁺ ions. This channel is activated by signaling pathways involving phospholipase C and diacylglycerol, functioning as a receptor-activated channel and, in some systems, as a store-operated channel. TRPC7 is expressed in various tissues, often alongside related channels like TRPC3 and TRPC6, and can form heteromultimeric complexes. It contributes to intracellular Ca²⁺ regulation and cellular signal transduction. While its physiological and pathophysiological significance is not as thoroughly characterized as some other TRP channels, TRPC7 is implicated in cardiovascular and neurological contexts and is the subject of ongoing research on its precise roles in health and disease
- Other names
- TRPC7TRP7Capacitative calcium channel TRPC7Short transient receptor potential channel 7Transient receptor potential cation channel
02
Mechanism of action
Non-selective cation channel that is activated by membrane receptors coupled to phospholipase C (PLC) and by diacylglycerol (DAG) analogs, mediating calcium influx into the cell
03
Biological functions
Signal transductionCalcium ion transportRegulation of intracellular Ca²⁺ levels
04
Disease associations
Cardiovascular diseaseNeurodegenerative diseaseOther (emerging evidence in various pathophysiological conditions, but specific disease links remain less studied compared to other TRPC channels)
05
Safety considerations
As with many ion channels participating in Ca²⁺ signaling, theoretical safety concerns include the potential for disturbance in calcium homeostasis, arrhythmias, or altered cellular excitability, though no specific therapeutic safety profile exists for TRPC7 modulation
06
Interacting drugs
No specific drugs directly targeting TRPC7 are currently approved or well-documented; research compounds or TRPC inhibitors such as SKF-96365 are sometimes used in experimental settings but are not specific for TRPC7
07
Biomarkers
No widely established TRPC7-specific biomarkers for clinical patient selection or efficacy monitoring as of current scientific consensus
Beyond the preview
Go deeper on Transient receptor potential cation channel subfamily C member 7 (TRPC7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transient receptor potential cation channel subfamily C member 7 (TRPC7).